FDA Upgrades Vitruvias Thyroid Medication Recall to Class I: Details and Symptoms

Federal health regulators have elevated a nationwide recall of Vitruvias Therapeutics thyroid tablets to a Class I recall, the most urgent safety classification issued by the Food and Drug Administration (FDA). The action impacts lot 504950 of 30 mg Thyroid Tablets, USP, after laboratory testing confirmed the pills may be superpotent and deliver far more active hormone than intended.

With 1,955 bottles sold across the United States out of 3,655 released units, taking tablets from this batch risks shifting the body into severe hyperthyroidism. The elevated potency creates immediate metabolic strain that can trigger serious cardiovascular events if left unchecked.

Inside the Vitruvias Therapeutics Thyroid Medication Recall

The affected bottles were distributed across wholesale and retail channels between January 31, 2025, and September 30, 2025, carrying an expiration date of September 30, 2026. Vitruvias Therapeutics initiated the voluntary withdrawal after discovering the strength discrepancy, proactively contacting wholesalers to halt distribution and coordinate product destruction.

Because thyroid hormone therapy relies on precise microgram-level dosing, even minor variations in strength can drastically disrupt physiological equilibrium. When tablets exceed established potency standards, normal hormone balance is instantly compromised.

Superpotency Risks and Cardiovascular Hazards

Consuming superpotent thyroid medication floods the bloodstream with excessive thyroid hormones, artificially inducing an overactive thyroid state. This hypermetabolic condition places immense mechanical stress on the circulatory system.

The FDA defines a Class I recall as “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

Physical warning signs include sudden heat intolerance, fatigue, muscle weakness, nervousness, and unexplained weight loss. More critically, superpotency can manifest as acute hypertension, chest pain, rapid heart rate, or complex cardiac rhythm disturbances that require emergency intervention.

Myth vs. Reality: Handling Recalled Prescriptions

A widespread assumption among consumers is that any recalled medication should be tossed in the trash immediately. In endocrine care, abruptly halting thyroid replacement without medical supervision can trigger rapid metabolic crashes and severe hypothyroidism symptoms.

Another common misconception is that all Vitruvias thyroid products are dangerous. Regulatory filings confirm this Class I designation applies strictly to 30 mg bottles under lot 504950, leaving other production batches unaffected.

Action Steps for Patients Holding Recalled Tablets

Patients who rely on daily thyroid management should quickly verify their packaging against the official thyroid medication recall parameters using this practical checklist:

1. Check the bottle label: Locate the National Drug Code (NDC 69680-166-00) and verify whether the lot number reads 504950 with an expiration date of 9/30/2026.
2. Do not discontinue cold turkey: Continue your daily regimen until you have contacted a qualified physician or dispensing pharmacist for a replacement strategy.
3. Schedule a clinical review: Contact your prescribing doctor immediately to arrange a replacement prescription and evaluate whether blood tests are needed.
4. Contact the manufacturer: Reach out directly to Vitruvias Therapeutics by calling 256-239-9373 or emailing [email protected] with specific product questions.

💡 Check your medicine cabinet today to confirm whether your prescription matches lot 504950 before taking your next scheduled dose.

🔍 Have you reviewed your prescription label or noticed unusual symptoms? Share your experiences in the comments below to help raise awareness.

📌 Send this safety update to friends and family members who manage thyroid conditions to keep them protected.